P. Y. Chan

Scientific Programme Committee

Ladislav, N. Rosenfeld, J. Reimand, 2000 .

A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma

P. Szlosarek, J. Bomalaski, M. Sheaff, 2022, Pigment cell & melanoma research.

A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity

P. Szlosarek, P. Y. Chan, V. Cohen, 2017, Pigment cell & melanoma research.

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers

G. Cook, P. Szlosarek, J. Spicer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer

P. Szlosarek, J. Bomalaski, M. Sheaff, 2021, Cancer medicine.

ctDNA monitoring using patient-specific sequencing and integration of variant reads

N. Rosenfeld, C. Caldas, J. Abraham, 2020, Science Translational Medicine.

The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis

D. Berney, Yong-jie Lu, J. Shamash, 2017, Clinical Cancer Research.

Phase 1 study of pegargiminase combined with cisplatin and pemetrexed in patients with ASS1-deficient uveal melanoma.

P. Szlosarek, J. Bomalaski, M. Sheaff, 2018 .

Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma

P. Szlosarek, I. Karydis, C. Ottensmeier, 2016, Oncoimmunology.

Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells.

D. Berney, Yong-jie Lu, J. Shamash, 2019, The Journal of urology.

High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads

N. Rosenfeld, G. Bignell, C. Parkinson, 2019, bioRxiv.